Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market From 2025 to 2029?
In recent times, there has been a consistent increase in the size of the chronic obstructive pulmonary disease (COPD) treatment market. Its value is projected to escalate from $20.84 billion in 2024 to $21.73 billion in 2025, with a compound annual growth rate (CAGR) of 4.3%. The expansion during the historical phase is due to the widespread issue of smoking and tobacco consumption, technologically enhanced inhalation treatments, awareness schemes and early detection, governmental actions for respiratory wellbeing, as well as research and progress in the field of pulmonology.
It is anticipated that the market size for treatments for chronic obstructive pulmonary disease (copd) will experience significant growth in the coming years, reaching “$27.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%.” Factors contributing to this growth during the forecast period include advancements in personalized medicine and biomarker research, the use of biologic therapies and targeted interventions, concerns over air quality and environmental factors, worldwide initiatives to end smoking, and partnerships for drug development. Key trends expected during this period encompass digital health solutions for managing COPD, biologic treatments for COPD, the rise of personalized medicine, combined therapies and inhalers, earlier diagnosis and intervention, and programs for pulmonary rehabilitation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
What Elements Are Contributing To Growth In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The escalating occurrence of lung disorders is predicted to stimulate the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung diseases, including the likes of asthma, COPD, and lung cancer, interfere with the normal operations of the lungs. The primary function of the chronic obstructive pulmonary disease (COPD) treatment is to tackle lung diseases, slow down the condition’s progression, manage the symptoms, and prevent lung damage through the use of inhalers and medications. For example, as per the global initiative for Chronic obstructive lung disease (GOLD), a US-based non-profit organization, in September 2022, a staggering 3.2 million people die from the chronic obstructive pulmonary disease (COPD) annually, impacting an estimated 200 million individuals in total. Besides, asthma was reportedly seen in 262 million individuals around the world in 2022, and these statistics are predicted to surge in future. Furthermore, the LUNGevity Foundation, another US-based non-profit organization, suggests that in 2023, lung cancer will cause 127,000 American deaths annually. Thus, the mounting prevalence of lung diseases plays an instrumental role in fueling the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
Which Segments Are Detailed In The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Which Trends Are Redefining The Future Landscape Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry?
The increasing push for product innovation is a leading trend in the market for chronic obstructive pulmonary disease (COPD) treatment. Firms in the sector are concentrating their efforts on creating novel products to maintain their market position. For example, GlaxoSmithKline plc (GSK), a British pharmaceutical and biotech firm, introduced Trelegy Ellipta in April 2022. This product, which contains fluticasone furoate, umeclidinium, and vilanterol, is India’s first single-inhaler triple treatment (SITT) for those suffering from chronic obstructive pulmonary disease (COPD). Trelegy Ellipta, designed for individuals aged 18 and above, works as a preventative and treatment solution for the indications of chronic obstructive pulmonary disease (COPD). The treatment works in a similar way to natural corticosteroid hormones, binding to receptors on specific immune cells, resulting in lowered immune system activity. Furthermore, it assists in reducing lung inflammation, aiding in easier breathing.
Who Are The Key Contributors To Growth In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.
Get The Full Report Here:
Which Region Is Projected To Lead The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market By 2025?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
